Dutch company receives €20 million for skin cancer diagnostic test3 Sep 2019
The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.
Benelux' largest biotech investor Aat van Herk has agreed to commit a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx' market potential of over $1 billion annually based on their current progress in the melanoma (skin cancer) field.
This melanoma test was discovered by a renowned US hospital and further optimized and developed by SkylineDx. Based on the unique combination of genetic information from the primary melanoma cells and other patient and tumour characteristics, the test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove (part of the) lymph nodes. Expert physicians estimate that up to 80% of these biopsies could be safely avoided as they turn out to have no sign of cancerous cells.
"This capital commitment is a very significant call of confidence," says Dharminder Chahal, CEO SkylineDx. "With the financial requirements secured and Professor Alexander Eggermont on board as our medical advisor, we can initiate the necessary clinical studies in collaboration with expert physicians, patient associations and other stakeholders, in order to get this test from bench to bedside and reimbursed."
Professor Alexander Eggermont is the general director of cancer center Gustave Roussy in Paris and a highly respected expert physician in the melanoma space.
"It is a great feeling that our efforts are lining up, getting our dream – to improve a patient's quality of life by enabling them to benefit from personal insights at the genetic level of their disease - within reach," concludes Dharminder Chahal.
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies
8 Nov 2019
But personalized medicines will require new logistics and manufacturing systems.Read more
Recipharm launches new service to support companies with QC and analytical requirements
1 Nov 2019
Services including method development, method validation, and stability program design and implementation.Read more
FDA approves first and only medicine in a new class of acute treatment for migraine
15 Oct 2019
The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.Read more
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio
14 Oct 2019
Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.Read more
Funding to accelerate delivery of Univercells' vaccine portfolio
11 Oct 2019
European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.Read more
Industrial-scale manufacture of therapeutic exosomes
10 Oct 2019
Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.Read more
BASF and Biomillenia join forces in microbiome research to promote healthy skin
7 Oct 2019
Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.Read more
Arctoris secures funding to advance novel robotic drug discovery platform
1 Oct 2019
Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,Read more
Data on lead ADC demonstrates effective tumour regression
1 Oct 2019
IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.Read more
Researchers develop less toxic anti-cancer drug
24 Sep 2019
New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation